- Home
- AIRI vs HOTH Comparison
AIRI vs HOTH Comparison
Compare AIRI & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- HOTH
- Stock Information
- Founded
- AIRI 1979
- HOTH 2017
- Country
- AIRI United States
- HOTH United States
- Employees
- AIRI N/A
- HOTH N/A
- Industry
- AIRI Military/Government/Technical
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- HOTH Health Care
- Exchange
- AIRI Nasdaq
- HOTH Nasdaq
- Market Cap
- AIRI 13.4M
- HOTH 15.6M
- IPO Year
- AIRI N/A
- HOTH 2019
- Fundamental
- Price
- AIRI $3.33
- HOTH $1.16
- Analyst Decision
- AIRI
- HOTH Strong Buy
- Analyst Count
- AIRI 0
- HOTH 3
- Target Price
- AIRI N/A
- HOTH $4.00
- AVG Volume (30 Days)
- AIRI 100.8K
- HOTH 302.2K
- Earning Date
- AIRI 08-18-2025
- HOTH 05-12-2025
- Dividend Yield
- AIRI N/A
- HOTH N/A
- EPS Growth
- AIRI N/A
- HOTH N/A
- EPS
- AIRI N/A
- HOTH N/A
- Revenue
- AIRI $53,182,000.00
- HOTH N/A
- Revenue This Year
- AIRI N/A
- HOTH N/A
- Revenue Next Year
- AIRI $4.99
- HOTH N/A
- P/E Ratio
- AIRI N/A
- HOTH N/A
- Revenue Growth
- AIRI 0.29
- HOTH N/A
- 52 Week Low
- AIRI $3.00
- HOTH $0.59
- 52 Week High
- AIRI $9.44
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- AIRI 42.87
- HOTH 39.91
- Support Level
- AIRI $3.32
- HOTH $1.26
- Resistance Level
- AIRI $3.45
- HOTH $1.40
- Average True Range (ATR)
- AIRI 0.09
- HOTH 0.09
- MACD
- AIRI -0.02
- HOTH -0.02
- Stochastic Oscillator
- AIRI 12.00
- HOTH 4.69
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).